Literature DB >> 21642738

Navigating the complexity of ulcerative colitis: challenging case example.

Mark Lees1, Loren Regier, Brent Jensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21642738      PMCID： PMC3093593     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  18 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

3.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.

Authors:  Charles N Bernstein; Michael Fried; J H Krabshuis; Henry Cohen; R Eliakim; Suleiman Fedail; Richard Gearry; K L Goh; Saheed Hamid; Aamir Ghafor Khan; A W LeMair; Qin Ouyang; J F Rey; Ajit Sood; Flavio Steinwurz; Ole O Thomsen; Alan Thomson; Gillian Watermeyer
Journal:  Inflamm Bowel Dis       Date:  2010-01       Impact factor: 5.325

4.  Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

Authors:  P Marteau; C S Probert; S Lindgren; M Gassul; T G Tan; A Dignass; R Befrits; G Midhagen; J Rademaker; M Foldager
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

6.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.

Authors:  M Safdi; M DeMicco; C Sninsky; P Banks; L Wruble; J Deren; G Koval; T Nichols; S Targan; C Fleishman; B Wiita
Journal:  Am J Gastroenterol       Date:  1997-10       Impact factor: 10.864

Review 7.  Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Authors:  Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 8.  Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  John K Marshall; Marroon Thabane; A Hillary Steinhart; Jamie R Newman; Anju Anand; E Jan Irvine
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  A practical guide to vaccinating the inflammatory bowel disease patient.

Authors:  Sharmeel K Wasan; Stacey E Baker; Paul R Skolnik; Francis A Farraye
Journal:  Am J Gastroenterol       Date:  2010-01-26       Impact factor: 10.864

10.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

Authors:  J F Rahier; S Ben-Horin; Y Chowers; C Conlon; P De Munter; G D'Haens; E Domènech; R Eliakim; A Eser; J Frater; M Gassull; M Giladi; A Kaser; M Lémann; T Moreels; A Moschen; R Pollok; W Reinisch; M Schunter; E F Stange; H Tilg; G Van Assche; N Viget; B Vucelic; A Walsh; G Weiss; Y Yazdanpanah; Y Zabana; S P L Travis; J F Colombel
Journal:  J Crohns Colitis       Date:  2009-04-26       Impact factor: 9.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.